Key Takeaways
- Strong revenue, margin spike is temporary: Revenue grew 20.8% YoY, led by the US, while gross margin surged 732 bps to 59.7% on a raw material transition benefit that management explicitly says will not sustain.
- US order book is the engine: A $200 million US order book and a quarterly run rate trending at $40 million, with contracts that only started in September/October, set up a back-half-weighted year.
- Teva facility is scaling into its cost base: The plant is at 40-45% utilization with fixed overheads nearly fully committed, so incremental revenue now drops through at higher margins.
- Gross margin will normalize to 53-55%: The 59.7% print is a transition effect as high-cost inventory rolls off; raw material prices are flattening and the benefit is not repeatable.
- What to watch next quarter: Whether the US quarterly run rate accelerates from $40 million toward the promised $50 million, and how quickly gross margin compresses back toward the guided 53-55% band.
US Business: Order Book & Run Rate
- Order book strength: The US order book stands at $200 million, built by expanding product portfolios within existing customers rather than adding many new accounts. Contracts range from 2 to 4 years, and the product basket can be increased when contracts open up.
- Run rate trajectory: The US business is trending at around $40 million per quarter, but most contracts started only in September or October, so the first half of the year was largely lost. Management expects the run rate to trend toward $50 million by next year once a full 12-month cycle is in place.
- Customer consolidation is a net positive: Some customers are reducing stores or splitting businesses, which may create a drag, but product growth into those customers has doubled, overshadowing any headwinds. Retailer consolidation strengthens their profitability and viability.
- Competitive moat: Management attributes account expansion to a mix of price from economies of scale, service, product basket breadth, reliability, and the ability to service requirements.
- Inventory buildup is deliberate: Elevated inventory reflects new product launches into accounts, which require 4 to 5 months of stock built before customers begin taking product. Inventory will stay elevated until March, when the optimum order trend toward the planned order book is reached.
Mark Saldanha: "So, Akash, my vision is big, but it's not - I don't want to sound crazy in terms of giving a number right now because here we have quarterly calls."
Margin Dynamics: The Temporary Spike
- Gross margin surge is a transition effect: The 732 bps expansion to 59.7% was driven by a better product mix and the shift from high-cost inventory to lower-cost raw material. Raw material prices have improved from historic highs but are now flattening, so the benefit is a one-time inventory tailwind, not a new structural level.
- Management's explicit guidance: Gross margin is expected to normalize to the 53% to 55% range. The current print is "just a transition of what you will see out there."
- EBITDA margin held back by Teva and freight: EBITDA margin came in at 21.1%, impacted by the addition of new employees at the Teva facility and a sequential INR 20 crore increase in freight costs. Freight prices have since softened dramatically, from ~$6,000-$6,500 to ~$3,600-$3,700 in the last 30 days.
- Teva operating leverage ahead: The facility is operating at 40% to 45% utilization, with fixed overheads almost fully committed. Incremental revenue will not have a proportionate increase in other expenses, so operating leverage benefit is expected in coming quarters.
- EBITDA outlook: Management expects EBITDA to be stable in the range of 22% odd, with no foreseeable cuts.
Mark Saldanha: "I don't expect these numbers, the gross margin to sustain. This is just a transition of what you will see out there. But definitely, we should be around 53% to 55% gross margin level."
UK & Europe: The Next Growth Leg
- UK seasonality: Q2 is a softer quarter for the UK because of summer; the business picks up in Q3 and Q4 onwards. The US will remain the growth driver, followed by the UK as a potential market.
- UK Rx pipeline: The UK has quite a few Rx items being launched, with a large pipeline of high-end Rx and niche products expected in 2025. Management expects improvement in both topline and bottom line from these launches.
- Five-year UK plan: Management has a business module for the next five years to ensure the UK achieves new milestones.
- Europe as M&A priority: Europe is the focus region for geographic expansion and the priority for M&A. The company has been looking at European targets for slightly over a year. Domestic market M&A is always explored based on merit.
- M&A reality check: No deals are on the table presently. Management looks for value-accretive opportunities where they need to invest after acquiring, similar to the Teva deal. Valuations of available facilities are described as "crazy."
Mark Saldanha: "Believe me, we have tried. It's not as easy. You don't every day come across a Teva. So obviously some of the facilities available, the valuations are crazy."
Australia/New Zealand: Slow-Build OTC Opportunity
- Market character: A very conservative market where growth takes longer. The portfolio is more OTC-oriented, spanning pain, cough and cold, allergy, and digestive categories.
- Long-term ambition: Management believes the OTC portfolio can double revenue over time, with the market eventually reaching the $100 million mark. This is explicitly not a 1-2 year story.
- No near-term catalyst: The timeline is vague and the market's conservative nature means investors should not model rapid inflection.
Product & Rx Pipeline
- Growth categories: Pain, cough and cold, and digestive segments drove growth through market share gains, market penetration, and new product launches. The Rx vs OTC split saw no meaningful change.
- Launch cadence: New product launches are planned every month or every two months from now until March 2025, requiring inventory to be built for day-one launch.
- Rx pricing pressure: US Rx pricing pressure remains as challenging as always. The UK Rx pipeline, with high-end niche products expected in 2025, is where management sees improvement potential.
- Product mix tailwind: The better product mix that contributed to gross margin expansion is partly structural, but the raw material transition effect is the dominant driver of the spike.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue milestone | Achieve INR 3,000 crores; should be very close next year | Within 2 years |
| Gross margin normalization | Normalize to 53% to 55% range | Unspecified; implied near-term as transition effect rolls off |
| US quarterly run rate | Accelerate from ~$40 million to ~$50 million | By next year |
| Teva facility revenue | Trend at INR 800 crores odd | By next year |
| Teva capacity cap | Capacity expected to cap out at INR 800 crores plus; working on next steps for capacity enhancement, greenfield, or M&A | Unspecified |
| EBITDA margin | Stable in the range of 22% odd; no foreseeable cuts | Ongoing |
| Inventory normalization | Inventory to stay elevated until optimum order trend toward planned order book is hit | Till March |
| Product launch cadence | New launches every month or every two months | Now through March 2025 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Operating revenue | ₹641.9 cr, +20.8% YoY vs ₹531.2 cr |
| US & North America revenue | ₹304.2 cr, +36.8% YoY |
| Australia & New Zealand revenue | ₹63.6 cr, +31.3% YoY |
| Rest of World revenue | ₹27.5 cr |
| Gross margin | 59.7%, expanded 732 bps YoY from 52.4% |
| EBITDA | ₹135.7 cr (all-time high), +19.1% YoY |
| EBITDA margin | 21.1%, impacted by new employees at Teva facility and higher freight costs |
| Profit after tax | ₹97.8 cr, +16.6% YoY vs ₹83.9 cr |
| EPS | ₹2.1 |
| R&D expense | ₹10.7 cr, 1.7% of consolidated revenue |
| Cash balance | ₹657 cr as of 30th September 2024, debt-free |
| Teva facility revenue contribution | ~₹100 cr in Q2, current annual run rate ~₹440 cr |
| Teva facility capacity utilization | ~40% |
| US order book | $200 million |
| US quarterly revenue run rate | ~$40 million |
| Freight cost | ~₹60 cr in Q2, up from ~₹40 cr in Q1 |
| FY26 EBITDA guidance | ~22% |
| Revenue milestone target | ₹3,000 cr within the next two years |